强效和选择性共价抑制剂的结构导向设计,针对SARS-CoV-2类似帕帕因的蛋白酶
Mona Sharafi1,2, Wei Pin Teh1,2, Jeremy Green3
1Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, United States.
Journal of medicinal chemistry
|January 20, 2026
概括
研究人员开发了针对SARS-CoV-2类似帕帕因蛋白酶 (PLpro) 的新型共价抑制剂. 这些抑制剂显示出强大的抗病毒活性,为COVID-19治疗和未来的流行病准备提供了有前途的新策略.
科学领域:
- 病毒学 病毒学
- 药用化学 医学化学
- 药物发现 药物发现 药物发现
背景情况:
- 随着COVID-19的流行,人们迫切需要有效的抗病毒疗法.
- 针对COVID-19感染的现有治疗方法可能需要新的作用机制,以提高疗效和对抗耐药性.
- 严重急性呼吸道综合征冠状病毒2 (SARS-CoV-2) 帕帕因样蛋白酶 (PLpro) 是一个关键的病毒酶,对复制和病原发生至关重要,使其成为一个有吸引力的药物标.
研究的目的:
- 设计和开发针对SARS-CoV-2 PLpro酶的新型共价抑制剂.
- 评估这些抑制剂在体外和体内对SARS-CoV-2的抗病毒活性.
- 探索这些抑制剂对未来抗病毒药物开发和流行病准备的潜力.
主要方法:
- 针对SARS-CoV-2的共价抑制剂的结构导向设计和合成PLpro.
- 生物化学测试以确定抑制剂的强度和作用机制.
- 基于细胞的测试来评估针对SARS-CoV-2复制的抗病毒活性.
- 在SARS-CoV-2感染的小鼠模型中的体内疗效研究.
主要成果:
- 开发出具有较低纳米至亚纳米抗病毒活性的SARS-CoV-2 PLpro强有力的共价抑制剂.
- 确定了N-propargylamide作为一种有效的电友弹头,用于对PLpro.pro的共价抑制.
- 在SARS-CoV-2感染的小鼠模型中显著抑制病毒复制.
结论:
- 开发的共价PLpro抑制剂代表了针对SARS-CoV-2的有前途的新类抗病毒药物.
- 独特的N-propargylamide弹头为设计共价蛋白酶抑制剂提供了一种新的方法.
- 这些发现为进一步优化PLpro抑制剂作为COVID-19和未来病毒大流行的潜在治疗方法提供了坚实的基础.
更多相关视频
06:08Author Spotlight: A Pseudotype Virus System for Assessing Omicron Subvariants and Neutralizing Antibodies in SARS-CoV-2 Research
Published on: September 8, 2023
1.7K
07:13Swabbing the Urban Environment - A Pipeline for Sampling and Detection of SARS-CoV-2 From Environmental Reservoirs
Published on: April 9, 2021
4.6K
相关概念视频
02:46Covalent Bonding and Lewis Structures
60.7K
Compared to ionic bonds, which results from the transfer of electrons between metallic and nonmetallic atoms, covalent bonds result from the mutual attraction of atoms for a “shared” pair of electrons.
60.7K
01:29Covalent Bonds
160.3K
Overview
160.3K
01:08Covalent Bonds
10.0K
Overview
When two atoms share electrons to complete their valence shells, they create a covalent bond. An atom's electronegativity—the force with which shared electrons are pulled towards an atom—determines how the electrons are shared. Molecules formed with covalent bonds can be either polar or nonpolar. Atoms with similar electronegativities form nonpolar covalent bonds; the electrons are shared equally. Atoms with different electronegativities share electrons unequally,...
When two atoms share electrons to complete their valence shells, they create a covalent bond. An atom's electronegativity—the force with which shared electrons are pulled towards an atom—determines how the electrons are shared. Molecules formed with covalent bonds can be either polar or nonpolar. Atoms with similar electronegativities form nonpolar covalent bonds; the electrons are shared equally. Atoms with different electronegativities share electrons unequally,...
10.0K
02:18Network Covalent Solids
16.1K
Network covalent solids contain a three-dimensional network of covalently bonded atoms as found in the crystal structures of nonmetals like diamond, graphite, silicon, and some covalent compounds, such as silicon dioxide (sand) and silicon carbide (carborundum, the abrasive on sandpaper). Many minerals have networks of covalent bonds.
To break or to melt a covalent network solid, covalent bonds must be broken. Because covalent bonds are relatively strong, covalent network solids are typically...
To break or to melt a covalent network solid, covalent bonds must be broken. Because covalent bonds are relatively strong, covalent network solids are typically...
16.1K
02:04Covalently Linked Protein Regulators
8.7K
Proteins can undergo many types of post-translational modifications, often in response to changes in their environment. These modifications play an important role in the function and stability of these proteins. Covalently linked molecules include functional groups, such as methyl, acetyl, and phosphate groups, and also small proteins, such as ubiquitin. There are around 200 different types of covalent regulators that have been identified.
These groups modify specific amino acids in a protein....
These groups modify specific amino acids in a protein....
8.7K
01:28Structure-Activity Relationships and Drug Design
1.7K
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
1.7K